Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Tumor infiltrating lymphocyte therapy
38:03
38:03
Spela senare
Spela senare
Listor
Gilla
Gillad
38:03
Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline. Iovance recently submitted a marke…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The future of combination vaccines
24:44
24:44
Spela senare
Spela senare
Listor
Gilla
Gillad
24:44
The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness. Moderna is harnessing the power of its mRNA platform to develop vaccines…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New German biotech spins out to develop radiotherapeutics
18:35
18:35
Spela senare
Spela senare
Listor
Gilla
Gillad
18:35
Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s clinical pipeline includes PENTIXATHER, am Yttrium-90 based therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 b…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Challenging the European biotech funding status quo
36:36
36:36
Spela senare
Spela senare
Listor
Gilla
Gillad
36:36
There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s location affect fundraising? What is the best approach to successfully raise funds? What are the current trends in biotech f…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA
32:57
32:57
Spela senare
Spela senare
Listor
Gilla
Gillad
32:57
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer! Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) inc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
[Rebroadcast] How does AI assist drug discovery?
38:40
38:40
Spela senare
Spela senare
Listor
Gilla
Gillad
38:40
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer! Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial int…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The first mass-market cell therapy?
25:34
25:34
Spela senare
Spela senare
Listor
Gilla
Gillad
25:34
Aurion Biotech is a US biotech with a regenerative medicine platform, developing novel therapies to restore vision to millions of people in need. This week on the podcast, we have a conversation with CEO Greg Kunst about Aurion’s pipeline, and how the company’s treatment could be the first mass-market cell therapy available. The FDA has granted the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Cutting through the AI hype in drug discovery
26:13
26:13
Spela senare
Spela senare
Listor
Gilla
Gillad
26:13
LabGenius is a drug discovery company developing next-generation therapeutic antibodies. The company’s discovery platform, EVA, integrates several technologies drawn from the fields of artificial intelligence (AI), robotic automation and synthetic biology. LabGenius operates under a hybrid business model that involves partnering with large biotech …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How biotechs are revolutionizing acute on-chronic liver failure?
29:22
29:22
Spela senare
Spela senare
Listor
Gilla
Gillad
29:22
Acute on-chronic liver failure (ACLF) is a significant healthcare issue with high unmet needs for patients and clinicians, and a massive burden for healthcare systems. It cost more than $6bn in the US alone in 2021, with a drastic increase over the last 10 years. Genfit is a late-stage biopharma company taking on rare, life-threatening liver diseas…
…
continue reading
The field of radiotherapeutics is a hot topic currently, and so who better to talk about the subject than Ken Herrmann, a radiopharmaceutical academic expert, who is Professor of Nuclear Medicine at the Universitätsklinikum Essen, in Essen Germany, and two people from the company Molecular Partners: Patrick Amstutz, who is a co-founder and the CEO,…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Priovant - finding options to treat autoimmune diseases
30:05
30:05
Spela senare
Spela senare
Listor
Gilla
Gillad
30:05
US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company's lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses key cytokines linked to autoimmu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How ADCs can deliver death cap mushroom toxins to treat cancer
28:09
28:09
Spela senare
Spela senare
Listor
Gilla
Gillad
28:09
Heidelberg Pharma is a clinical stage biotech company developing antibody drug conjugates (ADCs). Its lead amanitin-based ADC product candidate, HDP-101, targets relapsed or refractory multiple myeloma. HDP-101 recently received orphan drug designation; it is currently in a phase I/IIa clinical trial, demonstrating first signs of clinical efficacy.…
…
continue reading
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 diabetes and LADA (latent autoimmune diabetes in adults). Diamyd is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. It has been granted Orphan Drug Designation in the U.S. as well as Fast Track Desi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Developing treatments for rare pediatric diseases
29:17
29:17
Spela senare
Spela senare
Listor
Gilla
Gillad
29:17
Rare diseases affect around 1 in 2,000 people. Many of the thousands of rare diseases are difficult to diagnose. Of the known rare diseases, about 80% have genetic causes. Leukodystrophies are a group of rare genetic disorders for which there is currently no curative therapy. This week on the podcast we are discussing novel treatments of rare pedia…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Can cell therapy tackle hearing loss?
31:00
31:00
Spela senare
Spela senare
Listor
Gilla
Gillad
31:00
Hearing loss is a huge – and growing – global challenge. Using its OSPREY platform, UK-based Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products to address sensorineural hearing loss, a significant global medical challenge. The company’s lead asset, Rincell-1, is designed to regenerate auditory neurons a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How biotech is tackling myasthenia gravis
28:50
28:50
Spela senare
Spela senare
Listor
Gilla
Gillad
28:50
June is myasthenia gravis awareness month. Myasthenia gravis is a chronic autoimmune disorder where antibodies destroy the communication between nerves and muscle, and this results in weakness of the skeletal muscles. It especially affects the voluntary muscles of the eyes, mouth, throat and/or limbs. It is most frequent in women from 20 and 30 and…
…
continue reading
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Making waves in cardiovascular disease treatment
21:02
21:02
Spela senare
Spela senare
Listor
Gilla
Gillad
21:02
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. This week, we have a conversation with the …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New ways to treat Duchenne muscular dystrophy
23:56
23:56
Spela senare
Spela senare
Listor
Gilla
Gillad
23:56
Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact. There are few treatments for DMD, although recent advances mean that males – who are primarily affected by DMD – can now sometimes survive into their 30s. More drug…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Overcoming clinical trial challenges
26:00
26:00
Spela senare
Spela senare
Listor
Gilla
Gillad
26:00
This week, we have a conversation about clinical trial design with Gen Li, the president and founder of Phesi, a global provider of patient-centric data analysis. Earlier this year, Phesi’s global analysis of all clinical trials conducted in 2023 revealed that more than a quarter (28%) of trials were cancelled during phase II – above the average at…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The biotech investment landscape in 2024
28:32
28:32
Spela senare
Spela senare
Listor
Gilla
Gillad
28:32
RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. The company invests in both public and private companies across their entire life cycle, with a focus on those addressing next-generation gene and RNA therapies, rare diseases, targeted oncological, cardi…
…
continue reading
Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain. The Doloromics pipeline is…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Colossal aims to bring back mammoth by 2028
38:24
38:24
Spela senare
Spela senare
Listor
Gilla
Gillad
38:24
Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. Its mission is to use CRISPR technology to bring back extinct animals, such as the mammoth, the thylacine, and the dodo. Since DNA was recovered in 2021 from mammoths frozen…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New treatments being developed for schizophrenia
25:31
25:31
Spela senare
Spela senare
Listor
Gilla
Gillad
25:31
It would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way. Recently, Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) announced a global collaboration and exclusive option-to-license agreement. This is to develop and commercialize Sosei Hepta…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Reformulating psychedelics for neurodegenerative diseases
41:37
41:37
Spela senare
Spela senare
Listor
Gilla
Gillad
41:37
There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient. Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How AI immune system mapping can boost drug discovery
28:46
28:46
Spela senare
Spela senare
Listor
Gilla
Gillad
28:46
Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. In this wee…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Is Tome writing the final chapter in genomic medicine?
33:11
33:11
Spela senare
Spela senare
Listor
Gilla
Gillad
33:11
Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding. The company has developed a new approach to gene editing, programmable genomic integration (PGI), which it says represents the final chapter in genomic medicines. We discussed the company’s formation and approach with the CEO and president of Tome, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming treatments for epilepsy
41:27
41:27
Spela senare
Spela senare
Listor
Gilla
Gillad
41:27
After decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation. One of the biggest reasons it’s trailed behind has been the difficulty in teasing out complex neurobiology – an understanding necessary to design novel medicines. Rapport Therapeutics is playing a significant role in turning the ti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How does AI assist drug discovery?
38:26
38:26
Spela senare
Spela senare
Listor
Gilla
Gillad
38:26
Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" canc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Biosimilars and what’s new in cell and gene therapies
37:17
37:17
Spela senare
Spela senare
Listor
Gilla
Gillad
37:17
This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and what’s new at Advanced Therapies Week. 00:40-02:30: About Cardinal Health 02:30-05:12: What is Cardinal Health’s …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
BioSenic developing severe knee osteoarthritis treatment
31:43
31:43
Spela senare
Spela senare
Listor
Gilla
Gillad
31:43
BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. The post hoc analysis of a phase 3 study found that a single injection of JT…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Boosting fertility by changing the vaginal microbiome
32:38
32:38
Spela senare
Spela senare
Listor
Gilla
Gillad
32:38
Freya Biosciences is a clinical-stage biotech company dedicated to reimagining women's health and redefining fertility for those previously deprived of options. With a focus on microbial immunotherapies, Freya addresses immune drivers underlying a range of reproductive health conditions. The company recently received $38 million Series A financing …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Epic Bio - gene editing without cutting DNA
32:43
32:43
Spela senare
Spela senare
Listor
Gilla
Gillad
32:43
Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discuss epigenetic editing, why it’s reversibl…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Could natural killer cells transform Alzheimer’s treatment?
28:14
28:14
Spela senare
Spela senare
Listor
Gilla
Gillad
28:14
A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer’s disease, with remarkable results. This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s treatment landscape. 00:58-02:55: About NKGen Biotech 02:56-05:39: Why is Alzhei…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Gene editing in the microbiome to treat acne
29:02
29:02
Spela senare
Spela senare
Listor
Gilla
Gillad
29:02
Eligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome. Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population. This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Tackling challenging diseases with vaccines
25:47
25:47
Spela senare
Spela senare
Listor
Gilla
Gillad
25:47
Vaxxinity, Inc. is a U.S.-based biotechnology company looking to develop vaccines for several hard-to-treat diseases such as Alzheimer’s and Parkinson’s. The company is pioneering a new class of medicines through its proprietary technology platform, which has enabled the innovation of novel synthetic peptide immunotherapy candidates to bring the ef…
…
continue reading
Is there a connection between worms being eradicated from the gut in the early 20th Century and an increase in allergies and autoimmune disease? This week, we have a conversation with Holoclara CEO Andrea Choe, who not only believes there is a connection, but also sees secretions from worms as a way to tackle such diseases. 01:31-06:05: About Holoc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Ipsen advances liver disease treatment
21:47
21:47
Spela senare
Spela senare
Listor
Gilla
Gillad
21:47
Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen. On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease. 00:56-00:49: Background information 01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New class of small molecule therapeutics introduced
26:35
26:35
Spela senare
Spela senare
Listor
Gilla
Gillad
26:35
On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience. 00:45-01:06: About Gate Bioscience 01:06-02:09: What are disease-causing extracellular proteins? 02:09-04:44: How have diseases caused by extracellular proteins been treated in the past? 04:4…
…
continue reading
Among other things, UK-headquartered company Phenotypeca has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries to reduce the costs of vaccines. The company’s CEO, Johnny Cordiner, and research and development director, Professor Ed Louis, tell us about the work, as well as the company and i…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Mending a broken heart with biotech
29:10
29:10
Spela senare
Spela senare
Listor
Gilla
Gillad
29:10
French company CellProthera has seen some remarkable results treating people who have had a heart attack. On this week’s podcast, the company’s CEO Matthieu de Kalbermatten tells us how it works. 01:00-03:29: About CellProthera 03:30-06:30: What are ProtheraCytes? 06:30-09:02: Is this a cure? 09:02-10:24: Is prevention the best option? 10:25-11:49:…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How quantum computing can accelerate drug discovery
28:45
28:45
Spela senare
Spela senare
Listor
Gilla
Gillad
28:45
On today’s podcast, Jean-Philip Piquemal, the chief scientific officer and co-founder of Qubit Pharmaceuticals, explains how the company’s Atlas platform is leading the way to more effective and safer drugs. 00:54-01:52: The history of Qubit Pharmaceuticals 01:52-04:04: What is the Atlas software? 04:04-05:18: Failing quickly is the key 05:19-06:53…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 69 – improving access to cell and gene therapy
37:06
37:06
Spela senare
Spela senare
Listor
Gilla
Gillad
37:06
This week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech. Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT). Ori has developed a proprietary, full stack manufacturing platform that …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 68 – rejuvenation with stem cells
29:43
29:43
Spela senare
Spela senare
Listor
Gilla
Gillad
29:43
This week, our guest on the podcast is Mark Kotter, founder of newly-created company clock.bio. clock.bio, a sister company to bit.bio, which Kotter also founded and is the CEO of, aims to extend and improve quality of life by reversing the harmful effects of time in our cells, harnessing the regenerative capabilities of human pluripotent stem cell…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 67 – natural killer cells
28:55
28:55
Spela senare
Spela senare
Listor
Gilla
Gillad
28:55
This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 66 – treating rare diseases with tRNA
32:08
32:08
Spela senare
Spela senare
Listor
Gilla
Gillad
32:08
Compared to the smallest mRNA molecule, which is 300 nucleotides long, the largest transfer RNAs (tRNA) is less than a third of the size at 76 nucleotides. Scientists at Alltrna are harnessing the unique biology of tRNAs to engineer a single tRNA medicine that could treat thousands of rare diseases that share the same genetic mutation. This year, A…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 65 – Disease X and pandemic preparedness
43:11
43:11
Spela senare
Spela senare
Listor
Gilla
Gillad
43:11
Disease X, a concept shrouded in mystery, represents the unknown pathogens that could unleash future epidemics or pandemics. In the wake of recent global health crises, our understanding of the profound impact of those pandemics has deepened. On this week’s podcast, we have a conversation with Hamilton Bennett, who led Moderna’s mRNA-1273 COVID-19 …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 64 – Precision immuno-oncology therapies
38:31
38:31
Spela senare
Spela senare
Listor
Gilla
Gillad
38:31
Despite the huge commercial success of PD-1 inhibitors and widespread use of checkpoint inhibitors such as anti-PD-1 or anti-CTLA4, 70 to 80% of patients still experience limited or no response to existing therapies. In response to this critical challenge, Portage Biotech is on a mission to expand the number of patients who derive long-term benefit…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 63 – Tackling cancer with STRIs
33:32
33:32
Spela senare
Spela senare
Listor
Gilla
Gillad
33:32
This week’s podcast is sponsored by Vetter. On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics. eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs (selective translation regulation inhibitors). eFFECTOR’s STRI product ca…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Beyond Biotech podcast 62 – cytokine-based drugs
33:42
33:42
Spela senare
Spela senare
Listor
Gilla
Gillad
33:42
As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like in…
…
continue reading